Filed Mar 17, 2026Period of report Mar 15, 20260001928727-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 16, 2026
Common StockF3F4
7,405
$34.69
$256.88K
96,717.3392
Direct
Filing footnotes · 4
F1Reflects performance-based restricted stock units that were previously granted on March 15, 2025, subject to the Company meeting certain stock performance objectives compared to the S&P 1000 Healthcare Index. On March 5, 2026 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 22,445 performance-based restricted stock units (100% of target) of which 25% vested upon the one year anniversary of the grant date. The remaining performance-based restricted stock units will vest in equal quarterly increments once every three months over a three-year period (on each May 15, August 15, November 15, and February 15, respectively).
F2Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.
F3This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2025.
F4The price reported in Column 4 is an exact price of $34.69 for all shares sold.
Randall a LippsDirector · CHAIRMAN, PRESIDENT AND CEO
4Rule 10b5-1 plan disclosed
Filed Dec 3, 2025Period of report Dec 1, 20250001227556-25-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 1, 2025
Common StockF1F2
28,250
$35.9679
$1.02M
386,648
Direct
Filing footnotes · 5
F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025.
F2The price reported in Column 4 is a weighted average price of $35.9679. The sold price range between $35.65 to $36.4746. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3Shares held in trust with Mr. Lipps' wife.
F4Shares held in trust for the benefit of Mr. Lipps' children.
F5The options were granted on 2/4/2016 with 25% vested on the one-year anniversary of the grant date and the reaming amount vesting ratably over a 36 month period. The options were fully vested on 2/4/2020.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.